An interventional study of fMRI and CONFMEM in Alzheimer Disease, Early Onset and Parkinson Disease, sponsored by Rennes University Hospital. Recruiting at 1 site in France. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by Rennes University Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 438 studies in Alzheimer Disease with a site in France — 81 open to participants now, 97 under way, 18 of them phase 3. Alzheimer Disease · France.
Among the 438 studies in Alzheimer Disease with a site in France, this one is the 189th largest by planned enrollment of the 341 interventional ones that give a count, is one of 20 that started in 2023, is one of 168 with no phase, reaches primary completion later than 25 of the 96 other live ones, and was the 373rd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →81 of the 438 studies in Alzheimer Disease with a site in France are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in France, United States, Australia and 2 more countries
Ages 50–90
Firalis SA · Sites in France
Ages 45+ · Healthy volunteers
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 60+ · Healthy volunteers
University Hospital, Toulouse · Sites in France
Ages 50–85
Central Hospital, Nancy, France · Sites in France
Ages 18–99
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
438 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 71 · Phase 3 87 · Phase 4 7
First in 2001; this study’s year is marked. 20 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 152 across the 341 interventional studies, 142 across the 94 observational. Of the 290 that completed or were terminated, 74 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
156 of 438 have an industry lead sponsor. The 10 most frequent:
Rennes University Hospital is the lead sponsor of 451 studies on the registry; 51 are open to participants now.
Rennes University Hospital has 3 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
31 of the studies in Alzheimer Disease with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06080659Rennes University HospitalNetwork-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity | 2026-11 |
| NCT02800395Hospices Civils de LyonInfluence of Oxidative Stress and Nutrition Biomarkers on the Cognitive Decline Evolution in Alzheimer Disease | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 438 studies in Alzheimer Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal connectome.
Alzheimer's (AD) and Parkinson's (PD) diseases are characterized by pre-clinical and asymptomatic phases, which can extend over decades, before progressing through different clinical stages where cognitive and/or motor symptoms appear. A major challenge for clinical neuroscience is the availability of reliable, non-invasive and inexpensive biomarkers to enable early diagnosis, be clinically relevant, and ideally contribute to prognosis and patient monitoring.
Current criteria, which are essentially clinical, have a relatively low diagnostic accuracy, which is unfortunately responsible for a delay in diagnosis, whereas it has been established that early diagnosis makes it possible to postpone the loss of autonomy, open up opportunities for clinical trials for patients, and, epidemiologically speaking, ultimately reduce the prevalence of major neurocognitive disorders.
Recent advances in neuroimaging techniques and connectome analysis have led to the identification of innovative biomarkers that reflect the disorganization of brain networks and are associated with clinical symptoms.
After participant inclusion, the experimental visit will take place over half a day, for patients with early-stage Alzheimer's or Parkinson's disease and for healthy control volunteers.
After clinical assessment, participants will undergo an MRI scan and then perform the CONFMEM experimental task.
The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).
The cerebral connectome will be assessed for each patient, with the aim of determining whether patterns can lead to pathology-specific markers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
DCS+ group:
- Meeting the diagnostic criteria for "subjective cognitive decline-plus" (Jessen criteria (Jessen et al., 2014).
Alzheimer's patients "Mild Cognitive Impairment due to Alzheimer's Disease," "MCI-MA":
- Meeting the diagnostic criteria for "Mild neurocognitive disorder due to Alzheimer's disease" (criteria of (Albert et al., 2011))
De novo" Parkinsonian patients, "MPdn":
- Presenting with newly diagnosed ("de novo") Parkinson's disease and free of cognitive deficits (criteria of Postuma et al., 2015 (Postuma et al., 2015))
Parkinsonian patients with "Mild Cognitive Impairment, "MCI-MP":
- Presenting Parkinson's disease associated with "mild neurocognitive impairment" (criteria of Litvan et al., 2012 (Litvan et al., 2012))
Exclusion Criteria:
Patients only
Healthy volunteers only
- Cognitive impairment ( score \< 26)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient with subjective cognitive decline, prodromal condition of Alzheimer's disease
Diagnostic Test: fMRI · Diagnostic Test: CONFMEM
Patient with mild neurocognitive disorder linked to Alzheimer's disease
Diagnostic Test: fMRI · Diagnostic Test: CONFMEM
early-stage or de novo Parkinson's disease patients with no cognitive deficits
Diagnostic Test: fMRI · Diagnostic Test: CONFMEM
Patient with mild neurocognitive disorder linked to Parkinson's disease
Diagnostic Test: fMRI · Diagnostic Test: CONFMEM
Healthy volunteers
Diagnostic Test: fMRI · Diagnostic Test: CONFMEM
functional MRI
The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).
Multimodal connectivity graph metrics across diseases
Multi-layer graph combining the functional and structural connectivity will provide an ideal framework for identifying multimodal features. The first layer corresponds to the functional connectivity where links represent the similarity between the fMRI signal from different cerebral regions (i.e. the nodes), using the cross-correlation. The second layer represents the structural connectivity where the edges are the fiber density between the nodes. Topological metrics of graph: 1/ the nodal centrality which quantifies how important a node is within a network, 2/ the betweenness defined as the ratio of the number of the shortest paths comprising the node to the total number of shortest paths in the graph, measures the hub property of the node and 3/ local efficiency which quantify the ability of a network to transmit information at the global and local level, will be compared between patients at-risk for Alzheimer's Disease, patients with Parkinson's Disease and healthy controls.
Time frame: 2 hours and 30 minutes
Multimodal connectivity graph metrics across stages of disease
Multi-layer graph combining the functional and structural connectivity will provide an ideal framework for identifying multimodal features. The first layer corresponds to the functional connectivity where links represent the correlation between the fMRI signal. The second layer represents the structural connectivity where the edges are the fiber density between the nodes. Topological metrics of graph: 1/ the nodal centrality which quantifies how important a node is within a network, 2/ the betweenness defined as the ratio of the number of the shortest paths comprising the node to the total number and 3/ local efficiency which quantify the ability of a network to transmit information, will be compared between patients at-risk for Alzheimer's Disease at the Subjective Cognitive Decline stage and at the Mild Cognitive Impairment stage. Similarly, patients with Parkinson's Disease without cognitive impairment and with Parkinson's Disease with Mild Cognitive will be compared.
Time frame: 2 hours and 30 minutes
Correlation between multimodal connectivity graph metrics and cognitive scores
Cognitive scores will include standard tasks (MOCA, Symbol Digit Modality Test - oral, Digit span, 16-items Free \& Cued Selective Reminding Test, 10/36 spatial recall test, Oral Letter-Number Sequencing test, D-KEFS Color-Word Interference Test, Benton Judgment of Line Orientation, CLOX clock-drawing test, Boston Naming Test, Animal fluency) and an experimental recognition memory task. As for the latter, the scores used will be the congruency effect during study (RT in milliseconds), global recognition accuracy, and the effect of congruency on subsequent memory (difference in recognition accuracy between congruent and incongruent trials at study).
Time frame: Up to 6 months (maximum delay between the study visit and the collection of standard tasks).
Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 36 months after the start.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 36 months is above that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.